SINGH RAJINDER 4
4 · ChemoCentryx, Inc. · Filed Apr 17, 2019
Insider Transaction Report
Form 4
SINGH RAJINDER
SVP, Research
Transactions
- Exercise/Conversion
Common Stock
2019-04-15$2.10/sh+33,000$69,300→ 43,614 total - Exercise/Conversion
Stock Option (right to buy)
2019-04-15−33,000→ 147,000 totalExercise: $2.10Exp: 2026-05-09→ Common Stock (33,000 underlying) - Sale
Common Stock
2019-04-15$12.96/sh−33,000$427,706→ 10,614 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $12.78 to $13.16 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- [F3]As of April 15, 2019, and prior to this transaction, the exercised options were fully vested.
- [F4]Not applicable.